Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChrysalis Inves Regulatory News (CHRY)

Share Price Information for Chrysalis Inves (CHRY)

Share Price is delayed by 15 minutes
Get Live Data
80.40    0.00 (0.00%)
Bid:
80.20
Ask:
81.90
Spread: 1.70 (2.12%)
Market Cap: £386.70m
CHRY Live PriceLast checked at - London Stock Exchange

Intraday Chrysalis Inves Share Chart

Update note from QuotedData

27 Feb 2025 15:39

RNS Number : 7680Y
Chrysalis Investments Limited
27 February 2025
 

Chrysalis Investments - Update from QuotedData

27th February 2025

Return to form

Chrysalis Investments Limited (CHRY) has experienced decent net asset value (NAV) and share price growth recently. With the bulk of the proceeds from the disposals of Graphcore and Featurespace received, and the term loan facility drawn down, CHRY is making good progress with its share buyback programme (see page 4). As of publication, 46,183,261 shares had been bought back, around 7.8% of CHRY's issued share capital, and this is boosting its NAV. CHRY has now returned about £45m of its £100m target and is well placed to press ahead with this, as it had a total liquidity position (available cash and credit) of approximately £144m at end December 2024.

The bulk of the portfolio is performing well - in its recent results, CHRY said that all portfolio companies have seen profits rise or losses narrow - and Klarna's IPO still looks likely at some point this year. While there is a good case that it might soon be time to make new investments, the focus for 2025 will remain on narrowing the discount to NAV, which is in much better shape than it was a year ago, but still has room for improvement.

Full Research:

https://quoteddata.com/research/chrysalis-investments-return-to-form-qd/

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: Marten & Co was paid to produce this note Chrysalis Investments Limited, and it is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the Financial Conduct Authority. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of the Financial Conduct Authority.

QUOTEDDATA50 Gresham Street | London EC2V 7AYTel: +44 (0) 20 3691 9430

www.quoteddata.com | research@quoteddata.com | www.martenandco.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFZGZZKNRGKZM
Date   Source Headline
29th Feb 20249:48 amRNSHolding(s) in Company
8th Feb 20242:52 pmRNSUpdate from QuotedData
31st Jan 20244:46 pmRNSHolding(s) in Company
29th Jan 20247:00 amRNSQuarterly NAV Announcement and Trading Update
29th Jan 20247:00 amRNSNotice of AGM and Notice of EGM
29th Jan 20247:00 amRNSAnnual Results
12th Dec 20231:17 pmRNSHolding(s) in Company
11th Dec 202311:25 amRNSHolding(s) in Company
5th Dec 20232:14 pmRNSPortfolio Update
4th Dec 20233:32 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSInvestment Management Arrangements Update
30th Oct 20237:00 amRNSQuarterly NAV Announcement and Trading Update
13th Oct 20237:30 amRNSShareholder Update and Consultation
25th Sep 202310:09 amRNSHolding(s) in Company
13th Sep 20233:44 pmRNSHolding(s) in Company
11th Sep 20235:03 pmRNSHolding(s) in Company
7th Sep 20234:07 pmRNSHolding(s) in Company
21st Aug 202312:17 pmRNSHoldings in Company
31st Jul 20237:00 amRNSQuarterly NAV Announcement and Trading Update
27th Jul 20234:37 pmRNSUpdate from QuotedData
27th Jun 20237:00 amRNSInterim Results
13th Jun 202310:20 amRNSHolding(s) in Company
9th Jun 202312:06 pmRNSHolding(s) in Company
1st Jun 20233:10 pmRNSPortfolio Update
25th May 20239:14 amRNSPortfolio Update
15th May 20237:00 amRNSPortfolio Update
4th May 202310:00 amRNSQuarterly NAV Announcement and Trading Update
19th Apr 20233:16 pmRNSChange of Registered Office
21st Mar 20235:14 pmRNSResult of AGM
1st Mar 20233:15 pmRNSNotice of AGM
10th Feb 202310:34 amRNSHolding(s) in Company
7th Feb 20234:26 pmRNSPortfolio Update
1st Feb 20237:00 amRNSQuarterly NAV Announcement and Trading Update
31st Jan 20237:00 amRNSAnnual Results
6th Jan 20233:20 pmRNSHolding(s) in Company
15th Dec 20221:17 pmRNSHolding(s) in Company
30th Nov 20227:30 amRNSCapital Markets Event
30th Nov 20227:00 amRNSUpdate on Performance Fee Arrangements
25th Nov 202212:18 pmRNSPortfolio Update
21st Nov 20228:30 amRNSQuarterly NAV Announcement and Trading Update
21st Nov 20227:00 amRNSQuarterly NAV Announcement and Trading Update
21st Sep 20222:47 pmRNSHolding(s) in Company
9th Sep 202212:36 pmRNSResearch from QuotedData
2nd Sep 202211:51 amRNSHolding(s) in Company
23rd Aug 20222:10 pmRNSDirector/PDMR Shareholding
22nd Aug 20227:00 amRNSQuarterly NAV Announcement and Trading Update
22nd Jul 202210:49 amRNSHolding(s) in Company
12th Jul 20227:00 amRNSPortfolio Update
11th Jul 20221:17 pmRNSPortfolio Update
30th Jun 20227:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.